A new look at node-negative breast cancer.

Area of Science:

• Oncology
• Biomarkers
• Breast Cancer Research

Background:

• Node-negative breast cancer is common globally, necessitating specific risk assessment.
• Current prognostic factors for node-negative breast cancer are insufficient for guiding chemotherapy decisions.
• The trend towards universal chemotherapy in node-negative disease highlights the need for better patient selection.

Purpose of the Study:

• To review current risk assessment and predictive factors for node-negative breast cancer.
• To identify the limitations of existing prognostic tools.
• To emphasize the need for novel biomarkers in adjuvant chemotherapy decision-making.

Main Methods:

• Review of existing literature on node-negative breast cancer prognostication.
• Discussion of established and emerging biomarkers (e.g., tumor grade, uPA/PAI-1, Oncotype DX®).
• Analysis of treatment decision algorithms and clinical trial data (e.g., Plan B trial).

Main Results:

• No single prognostic factor reliably guides chemotherapy decisions in node-negative breast cancer.
• Tumor grade lacks standardization, and web-based algorithms like Adjuvant! Online have limitations.
• Biomarkers such as urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) show promise but require fresh-frozen tissue.
• Genomic assays like Oncotype DX® are under evaluation, with ongoing trials investigating combined approaches.

Conclusions:

• Proper patient selection remains a critical challenge in adjuvant chemotherapy for node-negative breast cancer.
• Existing methods for risk stratification are inadequate for precise treatment guidance.
• Development and validation of additional biomarkers are essential to identify patients who will benefit from chemotherapy.